We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 17, 2022

Efficacy of Olaparib in Metastatic Castration-Resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations

Clinical Cancer Research

 

Additional Info

Clinical Cancer Research
Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2 or ATM Alterations Identified by Testing Circulating Tumor DNA
Clin. Cancer Res 2022 Nov 01;[EPub Ahead of Print], N Matsubara, J de Bono, D Olmos, G Procopio, S Kawakami, Y Ürün, R van Alphen, A Flechon, MA Carducci, YD Choi, SJ Hotte, E Korbenfeld, G Kramer, N Agarwal, KN Chi, S Dearden, C Gresty, J Kang, C Poehlein, EA Harrington, M Hussain

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading